Clinical trials: Concentration
ADHD, Substance Abuse
Attention Deficit Hyperactivity Disorder (ADHD) in Adolescents With Substance Use Disorders (SUD)
The purpose of this study is to determine the efficacy of osmotic-release methylphenidate (OROS-MPH) versus placebo for the treatment of ADHD in adolescents with SUD.
- Trial name
- NCT00264797
- Testing
- Methylphenidate (OROS-MPH)
- Where
- 12 sites in United States
- Volunteers
- 303 people
- Sponsor
- University of Cincinnati
Attention Deficit Hyperactivity Disorder, ADHD
Time Course of Response to Methylphenidate HCl ER Capsules in Children 6 to 12 Years With ADHD in Classroom Setting
The time course of response following one dose of a new methylphenidate hydrochloride extended release capsule is studied in children 6-12 years in a simulated laboratory classroom setting.
- Trial name
- NCT01269463
- Testing
- Methylphenidate Hydrochloride Extended Release Capsule
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Rhodes Pharmaceuticals, L.P.
Attention Deficit/Hyperactivity Disorder
A Safety/Tolerability and PK Study With Azstarys® in Children With ADHD
The is a multicenter, dose-optimized, open-label, safety/ tolerability and pharmacokinetic (PK) study with Azstarys® in children 4 and 5 years of age with attention-deficit/hyperactivity disorder (ADHD).
- Trial name
- KP415P02 (NCT05721235)
- Testing
- Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)
- Where
- 20 sites in United States
- Volunteers
- 123 people
- Sponsor
- Corium, Inc.
Attention Deficit Hyperactivity Disorder
Sequencing Treatments for Mothers With ADHD and Their At - Risk Children
We hypothesize that successfully treating maternal Attention Deficit Hyperactivity Disorder (ADHD) will have a beneficial effect that extends to the child.
- Trial name
- TMF (NCT01816074)
- Testing
- Vyvanse (lisdexamphetamine), Behavior Parent Training
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Seattle Children's Hospital
Healthy, Attention Deficit Hyperactivity Disorder
Control of Cognition (Naltrexone, Methylphenidate, and ADHD Study (NMAS))
The goal of this research is to understand the functioning of 'regulatory circuits' in the brain. We are also interested in how the medications methylphenidate and naltrexone affect these regulatory circuits.
- Trial name
- NMAS (NCT01993108)
- Testing
- Methylphenidate, Naltrexone
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Primary Open Angle Glaucoma, Ocular Hypertension
Ph2 Placebo-Controlled Study for Safety & Ocular Efficacy of SBI-100 Ophthalmic Emulsion in Pts w/ Elevated Eye Pressure
The goal of this clinical trial is to test in patients with glaucoma and elevated pressure in the eye. The main questions it aims to answer are: • ability to lower pressure in the eye • safety in the eye and the body of patients…
- Trial name
- NCT06144918
- Testing
- SBI-100 Ophthalmic Emulsion, 0.5%, SBI-100 Ophthalmic Emulsion, 1.0%
- Where
- 3 sites in United States
- Volunteers
- 56 people
- Sponsor
- Skye Bioscience, Inc.
Electrolyte Imbalance, Hyponatremia
V2 Receptor Effects on Fluid Regulation and Performance
This primary aim of this study was to critically assess whether or not sweat water content and sodium concentration were acutely regulated by dynamic changes in antidiuretic hormone (arginine vasopressin or AVP) acting on the…
- Conditions
- Electrolyte Imbalance, Hyponatremia, Hypernatremia
- Trial name
- NCT02084797
- Testing
- V2R (Vasopressin 2 receptor)
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Oakland University
Cholestasis
Linerixibat and Obeticholic Acid Drug Interaction Study in Healthy Subjects
In participants with inadequate response/intolerance to ursodeoxycholic acid (UDCA) taking obeticholic acid (OCA) who experience pruritus (due to primary biliary cholangitis [PBC], OCA, or both) the addition of linerixibat to OCA…
- Trial name
- NCT04053023
- Testing
- GSK2330672 (linerixibat), Obeticholic acid
- Where
- United Kingdom
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Attention Deficit Hyperactivity Disorder (ADHD), Deficient Emotional Self-Regulation (DESR)
Omega-3 Fatty Acid Supplementation to ADHD Pharmacotherapy in ADHD Adults With Deficient Emotional Self-Regulation Traits
The purpose of this study is to a) assess the efficacy of omega-3 fatty acids in the treatment of Deficient Emotional Self-Regulation (DESR) among stimulant treated Attention Deficit Hyperactivity Disorder (ADHD) adults, b)…
- Trial name
- NCT01399827
- Testing
- ADHD Medication, Omega-3 Fatty Acids
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Massachusetts General Hospital
Non-small Cell Lung Cancer, Pancreatic Cancer
Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15
Study to evaluate the efficacy, safety and tolerability of ponsegromab compared to placebo in patients with cancer, cachexia, and elevated GDF 15.
- Conditions
- Non-small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, Loss of Appetite
- Trial name
- PROACC-1 (NCT05546476)
- Testing
- ponsegromab
- Where
- 78 sites in United States, Australia and 9 more
- Volunteers
- 187 people
- Sponsor
- Pfizer
Leukemia, Myeloid, Chronic-Phase
Phase III Trial Evaluating the Effectiveness of a Dose Adjustment of Imatinib Mesylate on the Molecular Response
The Imatinib Mesylate at a dose of 400 mg / day is the standard treatment for patients with CML-CP. Recent studies show that the quality of response rate (complete cytogenetic response and major molecular response rate) is…
- Trial name
- MIM (NCT01827930)
- Testing
- Imatinib Mesylate 600 MG Oral Tablet, Imatinib Mesylate 400 MG Oral Tablet, Imatinib Mesylate
- Where
- France
- Volunteers
- 68 people
- Sponsor
- Institut Bergonié
Attention Deficit Hyperactivity Disorder
PART A: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and With mGluR Mutations
This is PART A of a 2-part, 6-week, double-blind, dose-optimization, parallel-group study in children and adolescents (ages 6-17 years) with ADHD with and without CNVs in specific genes implicated in glutamatergic signaling and…
- Trial name
- NCT03265119
- Testing
- AEVI-001
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
Cervical Degenerative Disc Disease, Radiculopathy
An Investigation of the Metal Concentration in Patients Implanted With the PRESTIGE LP™ Cervical Disc at Two Contiguous Levels in the Cervical Spine
This clinical study will assess the metal concentrations present in the blood serum of patients who receive surgical treatment with the PRESTIGE LP™ Cervical Disc at two contiguous cervical levels from C3-C7.
- Conditions
- Cervical Degenerative Disc Disease, Radiculopathy, Myelopathy
- Trial name
- NCT03062657
- Testing
- PRESTIGE LP™ Cervical Disc
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- Medtronic Spinal and Biologics
Hepatitis C Virus
A Study to Evaluate the Pharmacokinetic Effect of SCH 503034 (Boceprevir) on Methadone or Buprenorphine/Naloxone Plasma Concentrations (P08123)
In this study, participants on methadone or buprenorphine/naloxone maintenance therapy will be given boceprevir. Blood samples will be taken at specified intervals to find out whether boceprevir affects the pharmacokinetics of…
- Trial name
- NCT01396005
- Testing
- boceprevir, methadone, buprenorphine/naloxone
- Volunteers
- 21 people
- Sponsor
- Merck Sharp & Dohme LLC
Attention Deficit Hyperactivity Disorder
A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Naturalistic Setting
This Phase 3 pivotal efficacy trial will examine the effects of HLD200 (methylphenidate) in patients aged 6-12 years with ADHD in a naturalistic setting.
- Trial name
- NCT02520388
- Testing
- HLD200 methylphenidate hydrochloride (MPH) Capsules
- Where
- 21 sites in United States
- Volunteers
- 163 people
- Sponsor
- Ironshore Pharmaceuticals and Development, Inc
Social Anxiety Disorder
Attention, Teleconferencing and Social Anxiety
This study involves completing some online assessments and an intervention for social anxiety that all involve interactions with other people on a teleconferencing call.
- Trial name
- NCT04729803
- Testing
- Experimental: Attention Guidance + Exposure, Active Comparator: Exposure Alone, Experimental: Attention Control + Exposure
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- University of Texas at Austin
Attention-Deficit/Hyperactivity Disorder, Attention Deficit Disorder
Effect of Guanfacine Extended-Release on Attention Deficit Hyperactivity Disorder (ADHD)-Associated Insomnia
This study seeks to determine, using special sleep tests (polysomnography and actigraphy) if guanfacine extended release is able to improve nighttime sleep in children with ADHD - associated insomnia while improving daytime ADHD…
- Conditions
- Attention-Deficit/Hyperactivity Disorder, Attention Deficit Disorder, Insomnia, Sleep Disorders
- Trial name
- NCT01156051
- Testing
- Guanfacine extended-release tablets
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Children's Specialized Hospital
Healthy Participants
Bioavailability of Bosutinib Administered as Capsule Contents Mixed With Applesauce or Yogurt Relative to Intact Capsules Under Fed Condition
This study is intended to estimate the relative bioavailability of a single 500 mg dose of bosutinib when administered as capsule contents mixed with applesauce or yogurt to intact capsules under fed condition in adult healthy…
- Trial name
- NCT04916769
- Testing
- Bosutinib capsule
- Where
- Belgium
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Pfizer
Relative Bioavailability, AUC
Study in Healthy Subjects to Compare the Concentrations of the Omega-3 Fatty Acids EPA and DHA in Blood When Delivered as Three New Capsules in Relation to the Epanova® Capsule Under Fasting and Fed Conditions
This study is a randomized, open-label, cross-over study in healthy subjects performed at a single study center. The study is divided into two parts, Part 1 and Part 2.
- Conditions
- Relative Bioavailability, AUC, Cmax, Pharmacokinetics
- Trial name
- NCT02359045
- Testing
- D1400147, D14000136, D14000137
- Where
- United States
- Volunteers
- 137 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Aging
Noradrenergic Activity and Attention
Older adults demonstrate increased distractibility by task-irrelevant information which contributes to general cognitive impairment.
- Trial name
- NAA (NCT05120713)
- Where
- United States
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- University of Southern California